(VOX) Voxel S.A. - Ratings and Ratios

Voxel S.A. (WAR:VOX) is a key player in Polands healthcare sector, specializing in diagnostic imaging. Their services include MRI, CT scans, PET scans, teleradiology, ultrasound, X-rays, and neuroradiosurgery. This comprehensive approach positions them as a one-stop solution for advanced diagnostic needs.

Beyond imaging, Voxel has diversified into COVID-19 testing, neurological hospitals, and information systems for healthcare facilities. They also offer clinical tests, enhancing their role in Polands medical landscape. Their production and sale of radiopharmaceuticals add another layer to their service portfolio, showcasing a vertically integrated business model.

Financially, Voxel boasts a market cap of 1286.56M PLN, with a P/E ratio of 14.32 and a forward P/E of 14.62. Their P/B ratio is 4.52, and P/S is 2.94. These metrics indicate a company with stable growth and a strong market position, making it an attractive option for investors seeking exposure to healthcare and biotechnology in Poland.

In conclusion, Voxel S.A. is strategically positioned with a diversified service offering and a robust financial standing, making it a noteworthy consideration for investors and fund managers focused on the biotechnology sector.